share_log

Novavax | 10-Q: Q2 2024 Earnings Report

Novavax | 10-Q: Q2 2024 Earnings Report

诺瓦瓦克斯医药 | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/08 19:39

Moomoo AI 已提取核心信息

Novavax reported Q2 2024 revenue of $415.5 million, compared to $424.4 million in Q2 2023, driven by $386.3 million in licensing revenue from the Sanofi collaboration agreement. Product sales declined to $19.9 million from $285.2 million year-over-year. The company posted net income of $162.4 million versus $58.0 million in Q2 2023.Research and development expenses decreased 51% to $106.9 million, while SG&A expenses increased slightly to $101.3 million including $29.5 million in Sanofi transaction costs. The company ended the quarter with $1.1 billion in cash and investments, bolstered by a $500 million upfront payment from Sanofi and $188 million from stock sales.Under the Sanofi agreement, Novavax will continue commercializing its updated COVID-19 vaccine through the 2024-2025 season before transitioning primary commercial responsibility to Sanofi in 2025. The company is eligible for up to $700 million in development and commercial milestones plus royalties. Novavax remains on track to initiate Phase 3 trials for its COVID-Influenza combination and standalone flu vaccines in Q4 2024.
Novavax reported Q2 2024 revenue of $415.5 million, compared to $424.4 million in Q2 2023, driven by $386.3 million in licensing revenue from the Sanofi collaboration agreement. Product sales declined to $19.9 million from $285.2 million year-over-year. The company posted net income of $162.4 million versus $58.0 million in Q2 2023.Research and development expenses decreased 51% to $106.9 million, while SG&A expenses increased slightly to $101.3 million including $29.5 million in Sanofi transaction costs. The company ended the quarter with $1.1 billion in cash and investments, bolstered by a $500 million upfront payment from Sanofi and $188 million from stock sales.Under the Sanofi agreement, Novavax will continue commercializing its updated COVID-19 vaccine through the 2024-2025 season before transitioning primary commercial responsibility to Sanofi in 2025. The company is eligible for up to $700 million in development and commercial milestones plus royalties. Novavax remains on track to initiate Phase 3 trials for its COVID-Influenza combination and standalone flu vaccines in Q4 2024.
诺瓦瓦克斯医药报告了2024年第二季度营业收入为41550万，与2023年第二季度的42440万相比，由于与赛诺菲安万特合作协议的38630万许可收入推动。产品销售同比下降至1990万，较去年同期的28520万大幅减少。该公司公布的净利润为16240万，相较于2023年第二季度的5800万。研究和开发费用减少51%，降至10690万，而销售、一般和行政费用略微上升至10130万，其中包括2950万的赛诺菲交易费用。该公司结束季度时现金和投资总额达11亿，得益于赛诺菲的50000万预付款和18800万的股票销售收入。根据与赛诺菲的协议，诺瓦瓦克斯医药将继续通过2024-2025季度商业化其更新版COVID-19生物-疫苗，之后将在2025年将主要商业责任转交给赛诺菲。该公司有机会获得高达70000万的发展和商业里程碑款项以及特许权使用费。诺瓦瓦克斯医药仍然按计划在2024年第四季度启动其COVID-流感联合疫苗和单独流感疫苗的第三阶段临床试验。
诺瓦瓦克斯医药报告了2024年第二季度营业收入为41550万，与2023年第二季度的42440万相比，由于与赛诺菲安万特合作协议的38630万许可收入推动。产品销售同比下降至1990万，较去年同期的28520万大幅减少。该公司公布的净利润为16240万，相较于2023年第二季度的5800万。研究和开发费用减少51%，降至10690万，而销售、一般和行政费用略微上升至10130万，其中包括2950万的赛诺菲交易费用。该公司结束季度时现金和投资总额达11亿，得益于赛诺菲的50000万预付款和18800万的股票销售收入。根据与赛诺菲的协议，诺瓦瓦克斯医药将继续通过2024-2025季度商业化其更新版COVID-19生物-疫苗，之后将在2025年将主要商业责任转交给赛诺菲。该公司有机会获得高达70000万的发展和商业里程碑款项以及特许权使用费。诺瓦瓦克斯医药仍然按计划在2024年第四季度启动其COVID-流感联合疫苗和单独流感疫苗的第三阶段临床试验。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

独立文件8  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    热门讨论
    特朗普2.0时代开启，全球市场会如何演变？
    🎙️讨论： 1. 关税政策将如何影响美股、黄金、比特币等核心资产的走势？ 2. 在此背景下，有哪些投资机会值得关注？你会如何布局？ 展开
    MicroStrategy 2024年第四季度业绩电话会
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。